“NQO1Gene C609T Polymorphism (dbSNP: rs1800566) and Digestive Tract Cancer Risk: A Meta-Analysis.”

Possible association of HMOX1 and NQO1 polymorphisms with anti-tuberculosis drug-induced liver injury: A matched case-control study

“…In a study on human colon carcinoma cells, an SNP (rs1800566, 609C>T) in NQO1 leading to a non‐synonymous mutation (P187S) was found to be associated with low gene expression and enzymatic activity . Because NQO1 is involved in the detoxification of numerous endogenous and foreign compounds, it seems likely that the lack of NQO1 activity might increase the susceptibility to some diseases, such as breast cancer, nasopharyngeal carcinoma and digestive tract cancer . A previous study reported that the combined genetic polymorphisms involving specific genes (cytochrome P450 1A1, NQO1, glucose transporter 1, peroxisome proliferator‐activated receptors γ‐892 and γ‐1431) were associated with increased susceptibility to troglitazone (TGZ)‐induced liver injury in a cohort with 4079 patients .…”

“…32 Because NQO1 is involved in the detoxification of numerous endogenous and foreign compounds, it seems likely that the lack of NQO1 activity might increase the susceptibility to some diseases, such as breast cancer, 33 nasopharyngeal carcinoma 34 and digestive tract cancer. 35 A previous study reported that the combined genetic polymorphisms involving specific genes (cytochrome P450 1A1, NQO1, glucose transporter 1, peroxisome proliferator-activated receptors γ-892 and γ-1431) were associated with increased susceptibility to troglitazone (TGZ)-induced liver injury in a cohort with 4079 patients. 36 However, two other previous studies suggested that there was no significant difference in the genetic frequency of NQO1 between ATLI cases and controls.…”

Brain derived neurotrophic factor (BDNF) Val66Met polymorphism is not risk factor for bipolar disorder

“…Possible explanation for the lack of association between the Val66Met (rs6265) polymorphism and BPD in present metaanalysis may be due to (i) small sample size in included genetic association studies, (ii) different clinical criteria for selecting BPD patients and (iii) BDNF factor level decreases in subtype BPD II but not in BPD I. Meta-analysis is an acceptable powerful statistical tool which is used effectively to combine data from several similar case control studies to obtain reliable results. During past two decades, numerous meta-analysis were published which evaluated genetic polymorphism as risk factor for different diseases and disorders-likeschizophrenia , depression (Rai,2014), autism Rai and Kumar,2018), Glucose 6-phosphate deficiency , hyperuricemia , cleft lip and palate (Rai,2014(Rai, ,2017, male infertility (Rai and Kumar,2017), Down syndrome (Rai,2011;Rai and Kumar,2018), epilepsy , Uterine Leiomyoma , recurrent pregnancy loss , breast cancer (Rai,2014;, digestive tract cancer (Yadav et al,2018), colorectal cancer (Rai, 2015), esophageal cancer (Kumar and Rai,2018), ovary cancer (Rai,2016), and prostate cancer and endometrial cancer (Kumar and Rai,2018) etc. Despite the clear strengths of present meta-analysis, including relatively large sample sizes and lack of publication bias, the interpretation of results should be done in light of few limitations like-(i) crude ORs without adjustment was used as association measure, adjusted analysis could not be done due to lack of sufficient raw data about related risk factors like substance abuse, alcohol intake etc., (ii) significant heterogeneity was observed in overall metaanalysis,(iii) single gene polymorphism was considered, and (iv) gene-environment interactions were not considered.…”

MTHFR gene A1298C polymorphism and Alzheimer’s disease susceptibility

“…Meta-analysis is a statistical tool, which is successfully used for the compilation of contradictory results of small effect/power case-control studies. Several meta-analysis were published which evaluated risk of small effect gene polymorphism for different disease and disorders like-epilepsy [29], Alzheimer's disease [30], G6PD [31], Down syndrome [32][33][34], Uterine Leiomyoma [35], orofacial cleft [36,37], depression [38], schizophrenia [39,40], autism [41, , male infertility [42] digestive tract cancer [43], lung cancer [44], endometrial cancer [45], breast cancer [46,47], prostate cancer [48], colorectal cancer [49], and esophageal cancer [50] etc.…”